Antiproteinuric effect of recombinant human erythropoietin (rHuEPO) in predialysis chronic kidney disease (CKD) patients: multicenter observational study
Not Applicable
- Conditions
- Predialysis CKD patients treated with recombinant human erythropoietin (rHuEPO)
- Registration Number
- JPRN-UMIN000001634
- Lead Sponsor
- Osaka General Medical Center Department of Kidney Disease and Hypertension
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with cancer, liver cirrhosis, maintenance dialysis and pregnancy were excluded. Patients who were started or changed with antihypertensives or diuretics or who required admission within 6 months before- and after- rHuEPO initiation.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in proteinuria
- Secondary Outcome Measures
Name Time Method Correlation between reduction in proteinuria and increase in Hb.